

上海和黄药业

创新传统中药服务和谐社会

Service
harmonious
society


Innovate
traditional
Chinese Medicine

铸就  的长城

百年传承 起点唯高

With a century long heritage, we start at a higher level.

1



李嘉诚先生亲切接见上海和黄药业董事总经理周俊杰先生（左）

1734年 雷允上

1874年 胡庆余堂

1783年 童涵春堂

1882年 蔡同德堂

1958年

四家百年老店合并,成立上海中药制药一厂

2001年

和记黄埔和上药集团合资,上海和黄药业成立

上海和黄药业 —— 百年承传 起点唯高

上海和黄药业有限公司成立于2001年的8月，是由和记黄埔(中国)有限公司与上海市药材有限公司共同投资组建的上海首家中药合资企业，总投资额22,000万人民币。原上海中药制药一厂及“上药”牌注册商标等，转入合资企业。

上海中药制药一厂建于1958年，由沪上四家百年药店雷允上、胡庆余、童涵春、蔡同德合并而成，是一家具有优良传统、丰富经验、剂型全面，技术领先的老牌中药企业。

和记黄埔集团是香港李嘉诚先生属下的跨国性综合企业，是世界500强企业之一，在全球四十二个国家经营包括医药保健在内的多项业务，是中国大陆最主要的投资商之一。和记黄埔致力于中药全球化事业，自2000年始，已经分别在中国和欧洲成立了包括上海和黄药业在内的多项医药保健业务。

上海和黄药业依托和记黄埔强大的资金和管理实力，发扬和拓展其传统优势，已发展成为拥有丸剂、片剂、注射剂等12大类剂型，“上药”牌注册商标及麝香保心丸、胆宁片、生脉注射液等70个品种的知名中药生产企业，并为推动中药现代化的进程而不断努力。

2

SHANGHAI HUTCHISON PHARMACEUTICALS

Shanghai Hutchinson Whampoa Pharmaceutical Co., Ltd. was founded in August 2001, as the first joint venture in Chinese medicine jointly invested by Hutchinson Whampoa (China) Co., Ltd. and Shanghai Medicine Co., Ltd., with a total investment of 22,000,000RMB. The original Shanghai No. 1 Pharmaceutical Factory of Chinese Medicine and the registered trademark of "Shang Yao" will be transferred to the joint venture.

Shanghai No. 1 Pharmaceutical Factory of Chinese Medicine was established in 1958, jointly combined from four traditional brands of pharmacies in Shanghai - Lei Yun Shang, Hu Qing Yu, Tong Han Chun and Cai Tong De. It is an old brand of business in Chinese medicine with good tradition, rich experience, comprehensive products and leading technology.

Hutchinson Whampoa is a multi-national business under Li Ka-Shing's group. As one of the top 500 enterprises around the world, the company is engaged in diversified businesses including medicine and healthcare in 42 countries, ranking among the major investors in Chinese Mainland. Being committed to the globalization of Chinese medicine, Hutchinson Whampoa has established a variety of medicine and healthcare businesses in China and Europe since 2000, including Shanghai Hutchinson Whampoa Pharmaceutical.

Supported by strong financial background and management skills, Shanghai Hutchinson Whampoa Pharmaceutical is striving to implement and explore its traditional advantages. The company has grown into a famous manufacturer of Chinese medicine, including 12 types of medicine such as pill, tablet and injection, registered trademark of "Shang Yao" and 70 brands such as she xiang bao xin wan, dan ning pian, sheng mai injection fluid, and is still making constant efforts to promote the process of modernization of Chinese medicine.

上药牌-中国驰名商标

上药牌商标注册于1963年，广泛应用于产品外包装。1964年即开始了系列宣传活动，如上海市中心上药牌商标的大幅户外广告等。自此，上药牌商标不仅成为企业的主打品牌，同时也成为了上海中药的代表品牌。1997年，上药牌商标转让至上海市药材有限公司中药制药一厂，2001年转入上海和黄药业有限公司。

上药牌商标早在1980年便已荣获“国家著名商标”证书。1998年起上药牌商标连续13年被认定为“上海市著名商标”；2010年1月16日，中华人民共和国国家工商行政管理总局商标局评审认定“上药牌”商标为“中国驰名商标”。


截止目前，上药牌产品已获得全国性奖项12项、地方性奖项14项。



The trademark "shang yao" was registered in 1963, and is widely used in external packages of products. A series of promotion activities has begun since 1964, such as a large outdoor advertisement of the trademark "shang yao" in the city center of Shanghai. Since then, the trademark "shang yao" has become the dominant brand of the enterprise, as well as a representative brand of Shanghai TCM. The trademark "shang yao" was transferred to Shanghai No. 1 TCM factory in 1997, and was incorporated into Shanghai Hutchison Pharmaceuticals in 2001. The trademark "shang yao" was awarded the certificate of "National Well-known".

Trademark as early as in 1980. Since 1998, the trademark "shang yao" has been identified as "Shanghai Well-known Brand" for 13 years in a row. On 16 January 2010, the Trademark Office of the State Administration for Industry & Commerce of the People's Republic of China reviewed and identified the trademark "shang yao" as "Famous trademark of China".

Up to date, "shang yao" products has obtained 12 national awards and 14 local awards.



和记黄埔致力于中药全球化


Hutchison Whampoa is committed to the globalization of traditional Chinese medicine.

2001年8月，和记黄埔与上海医药共同投资组建上海和黄药业有限公司，成为和记黄埔集团在内地首家医药企业。之后，和记黄埔相继投资成立北京同仁堂和记医药投资有限公司、广州白云山和记黄埔中药有限公司、和记黄埔医药（上海）有限公司。目前，和记黄埔医药正在从事心脑血管、糖尿病、肿瘤及自身免疫性疾病等领域的新药开发，已有两个新药在美国进行二期临床试验。

和记黄埔大力推进中药国际化进程。2001年，在欧洲建立“和黄药业大药房”，拥有1000多家连锁店，兼营中西药；2003年，在伦敦推出“森（SEN）”中药店，向西方社会推广中医药文化。2006年5月，和记黄埔集团旗下和黄中国医药科技有限公司在伦敦上市，成为首家在英国上市的中药企业。中药全球化已经成为和记黄埔的战略核心业务。

In August 2001, Hutchison Whampoa and Shanghai Pharmaceutical (Group) Co., Ltd jointly invested to establish Shanghai Hutchison Pharmaceuticals, which became the first pharmaceutical company of Hutchison Whampoa in Mainland China. Later, Hutchison Whampoa successively invested to establish Beijing Tongrentang Hutchison Pharmaceutical Investment Co. Ltd and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co. Ltd, and found Hutchison MediPharma R&D Ltd in Shanghai Zhangjiang Hi-tech Park. Currently, Hutchison MediPharma R&D Ltd is engaged in the development of new drugs for cardiovascular and cerebrovascular diseases, diabetes, tumors and autoimmune diseases, and has two new drugs undergoing Phase II clinical trials in the USA.

Hutchison Whampoa is vigorously promoting the internationalization of traditional Chinese medicine. In 2001, Hutchison Whampoa established Hutchison Whampoa Pharmacy in Europe, which had more than 1,000 stores and sold both traditional Chinese medicine and western medicine. In 2003, Hutchison Whampoa launched "SEN" traditional Chinese medicine store, which promoted the culture of traditional Chinese medicine by starting with TCM oral tablets. In May 2006, Hutchison China MediTech Limited, subordinate to Hutchison Whampoa, was listed in London, and became the first TCM enterprise listed in the UK. At present, the globalization of Chinese traditional medicine has become the strategic core business of Hutchison Whampoa.



2006年5月，和记黄埔医药科技在伦敦上市



2000年
香港
同仁堂和记(香港)药业发展公司




2001年
上海
上海和黄药业有限公司




2001年
欧洲
和黄药业大药房1000多家连锁店



2002年
广州
和黄健宝保健品有限公司



2003年
北京
北京同仁堂和记医药投资有限公司



2003年
伦敦
“森(SEN)”中药店



2004年
上海张江
和记黄埔医药(上海)有限公司



2004年
广州
广州白云山和记中药有限公司

上海和黄药业致力于对传统中药的创新和发展，在“十一五”国家科技支撑计划项目及上海市科委“中药现代化专项”基金的资助下，与第二军医大学、清华大学合作对麝香保心丸开展深入的系列研究，从中分离得到95个纯化合物，并鉴定了其化学结构，阐明了物质基础，打破了“中成药成分不明确”的历史，并为制定中药复方标准、深入开展系统生物学研究奠定了基础；在“国家重大新药创制”科技专项的支持下，进一步破解麝香保心丸治疗冠心病的药物机理：我们还与中国中西医结合学会共同成立和黄科研基金，重点进行麝香保心丸促进治疗性血管新生的深入研究。在不断的创新投入下，麝香保心丸一直处于技术领先水平，被国家科学技术部和国家保密局认定为国家秘密技术保护品种，经过8000多万人安全使用，已成为防治冠心病的经典中成药。

7 Shanghai Hutchison Pharmaceuticals is committed to the innovation and development of traditional Chinese medicine. Being funded by "The 11th Five-Year Plan National key technology R&D" program and the fund of "Special Fund for TCM Modernization" of Science and Technology Commission of Shanghai Municipality, it cooperates with the Second Military Medical University and Tsinghua University to carry out deepened researched on heart protecting musk pill (HPMP), and has separated 95 pure compounds from it, identified its chemical structure, explained its substance base, and ending the history of "Unclear ingredients of Chinese patent medicine", and laid a foundation for establishing the TCM compounds standards and deepening the research on Systems Biology. With the support of the special project of "The new of medicine formulates major state", we will further explore the mechnism of how HPMP treats coronary diseases. It has been identified as a secret technology to be protected by the country by the Ministry of Science and Technology and National Administration for the Protection of State Secrets. After being used by more than 80 million patients, it proves to be the best choice in treating coronary diseases, and has become a classic Chinese patent medicine for prevention and treatment of coronary diseases.



创新点1

麝香保心丸促进治疗性血管新生

创新点3

麝香保心丸物质基础明确/主要成分代谢明确/入血成分明确

创新点5

系统生物学研究

创新点2

麝香保心丸各成分的生物活性

创新点4

麝香保心丸微粒丸制剂

创新点6

现代方法对中成药的临床和安全性评价



英国剑桥大学血管新生试验室主任樊台平教授（左）戴瑞鸿教授（右）

自20世纪70年代，医学家Folkman提出血管新生概念以来，麝香保心丸是第一个应用于临床，具有促进“治疗性血管新生”的中成药。

治疗性血管新生，即通过某些干预，在缺血心肌上调促进血管生长的细胞因子或受体，促进新的小血管生长，建立能够有效供血的侧支循环，达到改善心肌供血、改善患者症状和预后的目的。治疗性血管新生给冠心病治疗开辟了一个新的途径。

促进治疗性血管新生作用是麝香保心丸最独特之处，被称为“药物搭桥”，自2002年起，麝香保心丸促进治疗性血管新生的系列研究相继发表：能够促进血管生长因子的分泌、促进血管内皮管腔形成、促进动物模型缺血心肌周围的血管新生，通过对心肌缺血病人的影像学评估也发现麝香保心丸能改善缺血心肌血供。

2004年，麝香保心丸促进缺血心肌血管新生的研究成果发表在《生命科学（life sciences）》杂志，得到西方医学界的认可。

2006年，麝香保心丸促进血管新生系列研究荣获中国中西医结合学会科学技术奖。

2010年，剑桥大学与上海和黄药业签署相关研究协议，深入解析麝香保心丸的血管新生机制。

Since the 1970s when the physician Folkman put forwards the concept of Angiogenesis, HPMP was the first Chinese patent medicine which was widely used in clinical application and could promote therapeutic angiogenesis.

Therapeutic angiogenesis indicates that some intervention is used to activate cell factors or receptors which can promote angiogenesis on ischemic myocardium, promote the growth of new Small vessels, establish collateral circulation which can effectively supply blood, so as to restore blood supply to ischemic myocardium and improve the patient's symptoms and prognosis. Therapeutic angiogenesis has opened a new way for treating coronary diseases.

Promoting therapeutic angiogenesis is a distinct characteristic of HPMP, also known as "drug bridging". Since 2002, a number of researches on HPMP promoting therapeutic angiogenesis have been published in succession: it can promote the secretion of angiogenesis factors, promote the formation of vascular endothelial lumen, and promote therapeutic angiogenesis around the ischemic myocardium of animal models. It is also found to improve blood supply to ischemic myocardium by assessing the image characteristics of patient with myocardial ischemia.

In 2004, the research finding of HPMP promoting angiogenesis in ischemic myocardium was published in the magazine Life Sciences, and was recognized by western medical community.

In 2006, the finding on HPMP promoting angiogenesis was given the Scientific and Technological Award from the Association of the Integration of Traditional and Western Medicine.

In 2010, Cambridge University and Shanghai Hutchison Pharmaceuticals signed research agreement, according to which, Cambridge University will use three years to fully anatomize the mechanism of HPMP promoting angiogenesis.



葛均波

复旦大学附属中山医院心内科主任，心导管室主任
上海市心血管病研究所所长
复旦大学干细胞组织工程研究中心主任
复旦大学生物医学研究院双聘PI
教育部长江学者奖励计划特聘教授



范维琥

复旦大学附属华山医院心内科教授、主任医师、博士生导师
中国中西医结合学会心血管病专业委员会主任委员
国家中药制药工程技术研究中心生化与临床研究室副主任

第一个符合国际惯例的心血管中成药循证医学项目

传统中医学是建立在经验累积的基础上。随着循证医学理念的接受和严格随机对照临床研究在临床推荐级别中价值的肯定，证实中成药的安全、有效性就必须按照现代循证医学模式进行临床试验。

2009年，上海和黄药业启动了麝香保心丸大型循证医学课题。该研究采用随机、双盲、安慰剂对照原则，进行前瞻性、多中心、大样本研究，将对麝香保心丸治疗慢性稳定性冠心病患者疗效、安全性、远期心血管事件影响给予科学的评价，这也是国内第一个符合国际惯例的心血管中成药循证医学项目。

该课题由复旦大学附属中山医院葛均波教授、复旦大学附属华山医院范维琥教授牵头，在全国100多家三级甲等医院开展，预计在两年的随访期完成3000例慢性稳定性冠心病患者的临床观察，获得麝香保心丸改善患者生存质量、减少心血管事件的临床依据，使麝香保心丸更好地服务于临床，同时为中药现代化研究提供示范。对于传统中医药走向世界，也将产生积极的推动作用。

The first evidence-based medical program of Chinese patent medicine for cardiovascular diseases which conforms with international practices

Traditional Chinese medicine is based on the accumulation of experience. As the idea of evidence-based medicine is accepted and the value of strict randomly controlled clinical study in clinically recommended levels is recognized, it is necessary to carry out clinical trials by following modern evidence-based medicine model, in order to demonstrate the safety and efficiency of Chinese patent medicine.

In 2009, Shanghai Hutchison Pharmaceuticals launched a large evidence-based medical program for HPMP. This program used the principles of randomized, double-blind and placebo control, made a forward looking, multi-center, and large-sample research, and gave scientific evaluation on the efficiency and safety of HPMP in treating chronic stable coronary artery diseases and its impact on the future cardiovascular events. It is also the first evidence-based medical program of Chinese patent medicine for cardiovascular diseases which conforms with international practices.

This program was led by Professor Ge Junbo from Zhongshan Hospital of Fudan University and Professor Fan Weihu from Huashan Hospital of Fudan University, and was implemented in more than 100 AAA hospitals in China. It is expected that during 2 years of follow-up, clinical observation for 3000 cases of chronic stable coronary artery diseases will be completed and the clinical basis of HPMP in improving the quality of life of patients and reducing the occurrence of cardiovascular events will be obtained, so as to make HPMP better service for clinical purpose, and meanwhile, set up an example for the research of TCM modernization. It will also actively promote traditional Chinese medicine to go abroad.

传统中医药的独特疗效，来源其多组分、多靶点、多途径的整体药物作用。系统生物学是以整体性研究为特征的科学。对于传统中医药，可以通过系统生物学，从整体的角度了解中药物质组如何通过代谢组学、基因组学、蛋白组学在人体的应答系统中产生影响，从而发挥治疗作用。

在上海市中药现代化基金、国家自然科学基金、国家重大新药创制专项、十一五科技支撑项目的支持下，上海和黄药业与清华大学、第二军医大学等国内著名科研机构合作，针对麝香保心丸开展了持续深入系统生物学研究，并取得众多成果，发表于 *molecular biosystems* 等国际著名学术刊物，为推动传统中药现代化和国际化产生了深远影响。

The unique efficiency of traditional Chinese medicine comes from its multi-component, multi-target and multi-channel action of all drugs. Systems biology is a science characterized by integrity study. As for traditional Chinese medicine, systems biology can be used to understand, on a whole, how TCM materiome exerts an influence in the human response system via metabolomics, genomics, and proteomics, so as to play a role in treatment.


Being supported by the "Special Fund for TCM Modernization" of Shanghai Municipality, National Natural Science Funds, the Special Project of "Creation of Major New Drugs" and the Key Project of the National Eleventh-Five Year Research Program of China, Shanghai Hutchison Pharmaceuticals cooperates with domestic famous scientific research institutions such as the Second Military Medical University and Tsinghua University to carry out continuous and in-depth research on systems biology of HPMP, and has obtained many achievements, which have been published in international famous academic journals including *molecular biosystems*, and exerted profound influences on the promotion of modernization and internationalization of TCM.

系统生物学将是21世纪医学和生物学的核心驱动力

Leroy Hood 莱诺伊 胡德 系统生物学之父

人体是一个复杂的应答系统，需要对一个生物系统中所有组成成份（基因 mRNA 蛋白质）的构成，以及在特定条件下这些组分间的相互关系进行研究。系统生物学是以整体性研究为特征的一种大学科

麝香保心丸系统生物学研究




上海和黄药业拥有雄厚的科技实力和研发能力，为国家GMP认证企业，厂区占地43000平方米，生产工艺先进，技术力量雄厚，产品涵盖片剂、针剂、丸剂、口服液等12大类剂型。中国最早的复方中药注射液和最早的中药滴丸都从这里诞生，共首创产品32个，主要品种麝香保心丸和胆宁片都是公司投资开发的独家品种。2010年，公司获得上海市中药固体制剂工程中心，上海市企业技术中心，上海市科技小巨人企业等荣誉。目前公司已经建立起以企业技术中心和项目合作为主体的立体研发创新体系，依托和黄医药提供的强劲研发动力，重点开发心脑血管、消化系统等具有高科技含量和独立知识产权新药和新剂型。


和黄医药创新药物研发机构是中国最大，最有经验的创新药物团队之一，拥有丰富的全球创新药物研发经验。目前，正积极寻找有发展潜力的中药，以进一步开发，生产和推广，实现中药现代化及国际化。

As a GMP certified enterprise, Shanghai Hutchison Pharmaceuticals has profound technological strength and R&D capacity, with its plant covering a land of 43,000 square meters. It has advanced production process and profound technical strength, and its products include 12 main kinds of drug forms, such as tablet, injection, pill and oral liquid. The first compound TCM injection and the first TCM dropping pill in China all came from this company. It has originated 32 products, and its main products – HPMP and Danning tablet are exclusive products invested in and developed by the company. Being supported by the strong R&D strength provided by Hutchison MediPharma R&D Ltd, the company is focusing on the development of new drugs and new drug forms with high technological content and independent intellectual property rights in the field of cardiovascular and cerebrovascular diseases and digestive system.

The R&D institution for innovative drugs of Hutchison MediPharma R&D Ltd is one of the largest and best experienced teams for innovative drugs in China. It has rich global experience in the R&D of innovative drugs. Currently, it is actively seeking TCM with development potential, so as to further develop, produce and promote it, and realize TCM modernization and internationalization.



麝香保心丸国家秘密技术



麝香保心丸指纹图谱专利



上海市高新技术企业



上海外商投资先进技术企业

从1974年开始研发，上海和黄药业针对麝香保心丸的研究已经持续了30余年，发表研究论文400余篇。1981年，证实麝香保心丸能够快速扩张冠状动脉；1995年，发现了血管内皮保护作用；1998年，发现了减少心梗面积的特性；2002年，被证实为第一个能够促进治疗性血管新生的中成药；2009年，上海和黄药业对麝香保心丸启动了多中心、随机、双盲、安慰剂对照，计划近3000例观察的大型循证医学课题。麝香保心丸在冠心病防治中的价值，已从上市初期用于缓解心绞痛症状，扩展到针对冠心病多途径、多靶点发挥作用。

为了提高冠心病的社区管理水平、传播健康知识、有效抑制社区慢性疾病的发生。上海和黄药业与中国医师协会启动了“心希望工程”和“中西医结合治慢病继续医学教育项目”，培训临床医生十余万人。

From 1974, Shanghai Hutchison Pharmaceuticals has studied HPMP for more than 30 years, and published more than 400 papers. In 1981, it proved that HPMP could widen the coronary artery quickly. In 1995, it discovered that HPMP could protect vascular endothelium. In 1998, its unique function for reducing the area of myocardial infarction was found. In 2002, HPMP was proved to be the first Chinese patent medicine which could promote therapeutic angiogenesis. In 2009, Shanghai Hutchison Pharmaceuticals launched multicenter, double-blind and placebo control on HPMP, and planned a large evidence-based medicine topic with 3000 observed cases. The value of HPMP in prevention and control of coronary disease has expanded from just relieving symptoms of angina in the early stage after its launch, to multi-target therapy for coronary diseases.

In order to improve the management level on coronary diseases in communities, promote health knowledge, and effectively inhibit the occurrence of chronic diseases in communities, Shanghai Hutchison Pharmaceuticals and Chinese medical doctor association launched the "Heart Hope Project", as well as meetings on further education on treating chronic diseases by combining traditional Chinese medicine and western medicine, and has trained more than 100 thousand clinicians.



麝香保心丸之父
美国心脏学院院士
原华山医院副院长、内科主任
中国中西医结合学会心血管病委员会委员
中华医学会上海心血管病分会理事
复旦大学专家委员会委员
国家中药制药工程技术研究中心生化与临床研究室主任

戴瑞鸿教授



麝香保心丸临床用药交流



“心希望工程”医患携手社区健康促进行动



“中西医结合治慢病继续医学教育会议”



中国医师协会与和黄共同举行医师宣言活动